Retatrutide vs Survodutide
Comparing Eli Lilly's triple agonist retatrutide with Boehringer's dual GLP-1/glucagon agonist survodutide.
Last updated: February 1, 2026
Dossier labels summarize each dossier's research scope. They do not establish comparative treatment benefit or safety. Read the comparison below in that context.
Retatrutide
Dossier overview
Survodutide
Dossier overview
Overview
Retatrutide and survodutide represent two different multi-agonist approaches to obesity treatment. Retatrutide is Eli Lilly’s triple agonist (GLP-1/GIP/glucagon), while survodutide is Boehringer Ingelheim’s dual agonist (GLP-1/glucagon). Both include glucagon agonism but differ in GIP activity.
Mechanism Comparison
| Aspect | Retatrutide | Survodutide |
|---|---|---|
| GLP-1 Activity | Yes | Yes |
| GIP Activity | Yes | No |
| Glucagon Activity | Yes | Yes |
| Total Targets | 3 | 2 |
| Closest Comparator | Tirzepatide + glucagon | Oxyntomodulin-like |
Why GIP Matters
The difference between these drugs centers on GIP:
Retatrutide (with GIP):
- GIP enhances insulin secretion
- GIP may contribute to weight loss via central effects
- Proven concept from tirzepatide success
Survodutide (without GIP):
- Simpler dual mechanism
- Avoids potential GIP-related effects
- Focus on glucagon’s liver benefits
Evidence Comparison
| Aspect | Retatrutide | Survodutide |
|---|---|---|
| Development Phase | Phase 3 | Phase 3 |
| Key Trial | TRIUMPH program | Multiple Phase 2/3 |
| MASH Focus | Yes | Primary focus |
| Obesity Focus | Yes | Yes |
Weight Loss Comparison
Retatrutide (Phase 2)
| Dose | Weight Loss (48 weeks) |
|---|---|
| 8mg | ~22% |
| 12mg | ~24% |
Survodutide (Phase 2)
| Dose | Weight Loss (46 weeks) |
|---|---|
| 4.8mg | ~18-19% |
Note: Different trial designs; direct comparison not possible.
MASH/NASH Data
Both compounds show effects on liver disease:
| Outcome | Retatrutide | Survodutide |
|---|---|---|
| MASH Resolution | Being studied | Up to 83% (Phase 2) |
| Liver Fat Reduction | Significant | Significant |
| Fibrosis Improvement | Data pending | Demonstrated |
| Primary Indication | Obesity (MASH secondary) | MASH (primary focus) |
Survodutide has more advanced MASH-specific development.
Regulatory Status
| Aspect | Retatrutide | Survodutide |
|---|---|---|
| FDA Status | Investigational | Investigational |
| Phase 3 Programs | TRIUMPH (obesity, T2D) | MASH, Obesity |
| Developer | Eli Lilly | Boehringer Ingelheim |
| Expected Approval | 2026+ | 2025-2026 |
Side Effect Profile
| Effect | Retatrutide | Survodutide |
|---|---|---|
| Nausea | Common (dose-dependent) | Common |
| Vomiting | Common | Common |
| Diarrhea | Common | Common |
| Dose-limiting GI | Higher doses affected | Present |
Triple agonism may increase GI burden, but titration helps manage.
Administration
| Aspect | Retatrutide | Survodutide |
|---|---|---|
| Route | Subcutaneous | Subcutaneous |
Key Differences
| Factor | Retatrutide | Survodutide |
|---|---|---|
| GIP Activity | Yes | No |
| Weight Loss | ~24% (highest dose) | ~18-19% |
| MASH Focus | Secondary | Primary |
| Complexity | Triple agonist | Dual agonist |
| Developer | Eli Lilly | Boehringer Ingelheim |
Strategic Positioning
Retatrutide
- Positioned as maximum-efficacy obesity treatment
- Builds on tirzepatide success (adds glucagon)
- Lilly’s next-generation blockbuster
Survodutide
- Positioned for MASH indication
- Glucagon focus for liver benefits
- First-in-class for MASH if approved
Summary
- Retatrutide is a triple agonist showing ~24% weight loss - potentially best-in-class for obesity
- Survodutide is a dual agonist with strong MASH data and ~18% weight loss
- Both include glucagon agonism for enhanced metabolic effects
- GIP presence distinguishes mechanisms and possibly efficacy ceiling
- Different regulatory strategies: obesity vs MASH first-in-class
This comparison is for educational purposes only. Both compounds are investigational and not approved. Consult a healthcare provider for treatment decisions.
View Full Dossiers
Stay Updated on Peptide Comparisons
Get notified when we publish new comparison dossiers and evidence reviews.
No spam. Unsubscribe anytime.
Disclaimer: This comparison is for educational purposes only and does not constitute medical advice. Individual responses to medications vary. Always consult a qualified healthcare provider before making treatment decisions.